On Tue 26 Nov, Kenneth Ault wrote: > Hello - > > I am being told that our lab is having trouble finding a source for > labeled CD52 - apparently one or more companies have removed it from > their reagent line up. Does any one know the story on this? > > Thanks, > > Ken Ault I don't know if it is the explanation[*] but there is a press release on the Ilex Oncology website saying that they have recently obtained exclusive rights to Campath-1 (CD52) diagnostics. [*] BTG were assigned the full ownership of Campath in the late 80s early 90s and licensed it on for therapy. I think they have recently done the same for diagnostics. Mike <URL:http://www.path.cam.ac.uk/~mrc7/> -- M.R. Clark, PhD. Division of Immunology Cambridge University, Dept. Pathology Tennis Court Rd., Cambridge CB2 1QP Tel.+44 1223 333705 Fax.+44 1223 333875
This archive was generated by hypermail 2b29 : Sun Jan 05 2003 - 19:26:30 EST